Form 4: TriSalus Life Sciences Director William Valle Acquires Stock Options
SEC Form 4 Filing
Director William Valle of TriSalus Life Sciences acquired stock options for 41,250 shares of common stock on January 29, 2025.
Summary
- William Valle, a director at TriSalus Life Sciences, was granted stock options to purchase 41,250 shares of common stock.
- The options are divided into two grants: one for 35,000 shares and another for 6,250 shares.
- Both options have an exercise price of $4.89 per share and expire on January 28, 2035.
- The 35,000 share option vests in three equal annual installments starting January 29, 2025, contingent on continued service.
- The 6,250 share option fully vests on the one-year anniversary of the grant date, January 29, 2025, or at the next annual stockholder meeting, whichever is earlier, also contingent on continued service.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of stock options to a director, which is generally positive for aligning interests but not a major event.
Positives
- The granting of stock options to a director aligns their interests with the company's performance and shareholder value.
- The vesting schedule encourages continued service and commitment from the director.
Industry Context
This is a standard practice for incentivizing directors in publicly traded companies, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for directors in publicly traded companies, similar to practices at companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
- The vesting schedules are also typical, often tied to continued service to ensure long-term commitment, which is consistent with industry norms.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially leading to better company performance.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of the stock option grant and the commencement of vesting for the 35,000 share option. |
| 01/28/2035 | Expiration date of the stock options. |
| 01/31/2025 | Date the Form 4 was signed. |
Keywords
stock options, TriSalus Life Sciences, director, William Valle, equity, vesting, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.